Logo image of SSII

SS INNOVATIONS INTERNATIONAL (SSII) Stock Fundamental Analysis

USA - NASDAQ:SSII - US05453U2033 - Common Stock

6.95 USD
-0.24 (-3.34%)
Last: 10/6/2025, 2:31:50 PM
Fundamental Rating

1

Taking everything into account, SSII scores 1 out of 10 in our fundamental rating. SSII was compared to 191 industry peers in the Health Care Equipment & Supplies industry. SSII may be in some trouble as it scores bad on both profitability and health. SSII does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

In the past year SSII has reported negative net income.
SSII had a negative operating cash flow in the past year.
SSII Yearly Net Income VS EBIT VS OCF VS FCFSSII Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 -5M -10M -15M -20M

1.2 Ratios

With a Return On Assets value of -73.57%, SSII is not doing good in the industry: 72.77% of the companies in the same industry are doing better.
With a Return On Equity value of -200.25%, SSII is not doing good in the industry: 72.25% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -73.57%
ROE -200.25%
ROIC N/A
ROA(3y)-154.4%
ROA(5y)N/A
ROE(3y)-615.83%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SSII Yearly ROA, ROE, ROICSSII Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 0 -200 -400 -600 -800 -1K

1.3 Margins

SSII has a worse Gross Margin (31.96%) than 74.87% of its industry peers.
The Profit Margin and Operating Margin are not available for SSII so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 31.96%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SSII Yearly Profit, Operating, Gross MarginsSSII Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 0 -100 -200 -300

3

2. Health

2.1 Basic Checks

SSII does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SSII has more shares outstanding
The debt/assets ratio for SSII has been reduced compared to a year ago.
SSII Yearly Shares OutstandingSSII Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 50M 100M 150M
SSII Yearly Total Debt VS Total AssetsSSII Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 10M 20M 30M

2.2 Solvency

An Altman-Z score of 31.69 indicates that SSII is not in any danger for bankruptcy at the moment.
SSII has a Altman-Z score of 31.69. This is amongst the best in the industry. SSII outperforms 96.86% of its industry peers.
A Debt/Equity ratio of 0.87 indicates that SSII is somewhat dependend on debt financing.
SSII has a Debt to Equity ratio of 0.87. This is in the lower half of the industry: SSII underperforms 74.35% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.87
Debt/FCF N/A
Altman-Z 31.69
ROIC/WACCN/A
WACC8.75%
SSII Yearly LT Debt VS Equity VS FCFSSII Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 0 10M -10M

2.3 Liquidity

A Current Ratio of 1.41 indicates that SSII should not have too much problems paying its short term obligations.
SSII has a worse Current ratio (1.41) than 76.96% of its industry peers.
SSII has a Quick Ratio of 1.41. This is a bad value and indicates that SSII is not financially healthy enough and could expect problems in meeting its short term obligations.
SSII has a worse Quick ratio (0.92) than 80.63% of its industry peers.
Industry RankSector Rank
Current Ratio 1.41
Quick Ratio 0.92
SSII Yearly Current Assets VS Current LiabilitesSSII Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 5M 10M 15M 20M

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 41.04% over the past year.
SSII shows a strong growth in Revenue. In the last year, the Revenue has grown by 262.87%.
EPS 1Y (TTM)41.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-205.98%
Revenue 1Y (TTM)262.87%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%138.4%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SSII Yearly Revenue VS EstimatesSSII Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 1M 2M 3M 4M 5M

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SSII. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SSII Price Earnings VS Forward Price EarningsSSII Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SSII Per share dataSSII EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.05 -0.05 -0.1 -0.15

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

No dividends for SSII!.
Industry RankSector Rank
Dividend Yield N/A

SS INNOVATIONS INTERNATIONAL

NASDAQ:SSII (10/6/2025, 2:31:50 PM)

6.95

-0.24 (-3.34%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)09-04 2025-09-04
Earnings (Next)11-12 2025-11-12
Inst Owners0.18%
Inst Owner Change0%
Ins Owners75.32%
Ins Owner Change0%
Market Cap1.35B
AnalystsN/A
Price TargetN/A
Short Float %0.27%
Short Ratio1.67
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 82.09
P/FCF N/A
P/OCF N/A
P/B 96.85
P/tB 96.85
EV/EBITDA N/A
EPS(TTM)-0.16
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.05
FCFYN/A
OCF(TTM)-0.03
OCFYN/A
SpS0.08
BVpS0.07
TBVpS0.07
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -73.57%
ROE -200.25%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 31.96%
FCFM N/A
ROA(3y)-154.4%
ROA(5y)N/A
ROE(3y)-615.83%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.43
Health
Industry RankSector Rank
Debt/Equity 0.87
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1747%
Cap/Sales 21.5%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.41
Quick Ratio 0.92
Altman-Z 31.69
F-Score4
WACC8.75%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)41.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-205.98%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)262.87%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%138.4%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-361.37%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-1001.48%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-970.55%
OCF growth 3YN/A
OCF growth 5YN/A